These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 36652223)

  • 1. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
    Wheeler MT; Olivotto I; Elliott PM; Saberi S; Owens AT; Maurer MS; Masri A; Sehnert AJ; Edelberg JM; Chen YM; Florea V; Malhotra R; Wang A; Oreziak A; Myers J
    JAMA Cardiol; 2023 Mar; 8(3):240-247. PubMed ID: 36652223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial.
    Lee MMY; Masri A; Nassif ME; Barriales-Villa R; Abraham TP; Claggett BL; Coats CJ; Gimeno JR; Kulac IJ; Landsteiner I; Ma C; Maron MS; Olivotto I; Owens AT; Solomon SD; Veselka J; Jacoby DL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Lewis GD;
    JAMA Cardiol; 2024 Nov; 9(11):990-1000. PubMed ID: 39230885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
    Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
    Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment.
    Finocchiaro G; Haddad F; Knowles JW; Caleshu C; Pavlovic A; Homburger J; Shmargad Y; Sinagra G; Magavern E; Wong M; Perez M; Schnittger I; Myers J; Froelicher V; Ashley EA
    JACC Heart Fail; 2015 May; 3(5):408-418. PubMed ID: 25863972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
    Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
    Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
    Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
    J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
    Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
    JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy.
    Mapelli M; Romani S; Magrì D; Merlo M; Cittar M; Masè M; Muratori M; Gallo G; Sclafani M; Carriere C; Zaffalon D; Salvioni E; Mattavelli I; Vignati C; De Martino F; Rovai S; Autore C; Sinagra G; Agostoni P
    Heart; 2022 Sep; 108(20):1629-1636. PubMed ID: 35273123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ventilatory efficiency parameters outperform peak oxygen consumption in monitoring the therapy effects in patients with hypertrophic cardiomyopathy.
    Seman S; Tesic M; Babic M; Mikic L; Velicki L; Okwose NC; Charman SJ; Tafelmeier M; Olivotto I; Filipovic N; Ristic A; Arena R; Guazzi M; Jakovljevic D; Allison TG; Popovic D;
    Prog Cardiovasc Dis; 2024; 87():90-96. PubMed ID: 39424165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The characteristics of core parameters during cardiopulmonary exercise testing in patients with hypertrophy cardiomyopathy].
    Chen YZ; Sun XG; Tai WQ; Song Y; Shi C; Hao L; Wang JN; Hu XY; Zhang Y; Liu F
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2021 Jan; 37(1):65-71. PubMed ID: 34672465
    [No Abstract]   [Full Text] [Related]  

  • 14. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
    Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
    JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial.
    Wang A; Spertus JA; Wojdyla DM; Abraham TP; Nilles EK; Owens AT; Saberi S; Cresci S; Sehnert A; Lakdawala NK
    JACC Heart Fail; 2024 Mar; 12(3):567-579. PubMed ID: 37855754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure.
    Chase PJ; Kenjale A; Cahalin LP; Arena R; Davis PG; Myers J; Guazzi M; Forman DE; Ashley E; Peberdy MA; West E; Kelly CT; Bensimhon DR
    JACC Heart Fail; 2013 Oct; 1(5):427-32. PubMed ID: 24621975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between homocysteine and cardiopulmonary exercise testing in patients with acute coronary syndrome after percutaneous coronary intervention.
    Luo JT; Zeng CM; Zhao YM; Zeng ZY
    BMC Cardiovasc Disord; 2023 Jan; 23(1):3. PubMed ID: 36609219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventilatory response to carbon dioxide output in subjects with congestive heart failure and in patients with COPD with comparable exercise capacity.
    Teopompi E; Tzani P; Aiello M; Ramponi S; Visca D; Gioia MR; Marangio E; Serra W; Chetta A
    Respir Care; 2014 Jul; 59(7):1034-41. PubMed ID: 24046458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy: A Clinical Trial.
    Heitner SB; Jacoby D; Lester SJ; Owens A; Wang A; Zhang D; Lambing J; Lee J; Semigran M; Sehnert AJ
    Ann Intern Med; 2019 Jun; 170(11):741-748. PubMed ID: 31035291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope.
    Sarullo FM; Fazio G; Brusca I; Fasullo S; Paterna S; Licata P; Novo G; Novo S; Di Pasquale P
    Open Cardiovasc Med J; 2010 May; 4():127-34. PubMed ID: 20657715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.